aid: barinthus-biotherapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/barinthus-biotherapeutics.png
name: Barinthus Biotherapeutics
description: >-
  Barinthus Biotherapeutics plc (Nasdaq: BRNS) is a clinical-stage
  biopharmaceutical company developing novel immunotherapies designed to guide
  and reprogram T cells to overcome autoimmunity, inflammatory disease, chronic
  viral infection, and cancer. Its lead SNAP-TI and SNAP-CI antigen-specific
  platforms and ChAdOx/MVA immunotherapeutic candidates power a five-program
  pipeline including VTP-1000 (celiac disease), VTP-300 (chronic hepatitis B),
  VTP-200 (high-risk HPV), VTP-850 (recurrent prostate cancer), and VTP-1100
  (HPV-related cancer). The company was formed in 2021 through the merger of
  Oxford University spinout Vaccitech plc and NIH/Johns Hopkins spinout Avidea
  Technologies, and is headquartered in Germantown, Maryland with research
  facilities in the UK. It was surfaced as a portfolio company of Hongshan and
  added to the API Evangelist network. As a therapeutics company it publishes
  no public developer API, SDK, or agent surface.
url: https://raw.githubusercontent.com/api-evangelist/barinthus-biotherapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- hongshan
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
tags:
- Company
- Healthcare
- Biotechnology
- Biopharmaceutical
- Immunotherapy
- Autoimmune
- Oncology
- Clinical Stage
- Life Sciences
apis: []
common:
- type: DomainSecurity
  url: security/barinthus-biotherapeutics-domain-security.yml
- type: Website
  url: https://www.barinthusbio.com/
- type: About
  url: https://www.barinthusbio.com/about/
- type: Pipeline
  url: https://www.barinthusbio.com/pipeline/
- type: Support
  url: https://www.barinthusbio.com/contact/
- type: News
  url: https://investors.barinthusbio.com/news-filings/press-releases
- type: Investors
  url: https://investors.barinthusbio.com/
- type: PrivacyPolicy
  url: https://www.barinthusbio.com/data-protection-policy/
- type: LinkedIn
  url: https://www.linkedin.com/company/barinthusbiotherapeutics
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence